Eupraxia Pharmaceuticals's total assets for Q3 2025 were C$128.50M, an increase of 444.58% from the previous quarter. EPRX total liabilities were C$5.43M for the fiscal quarter, a 107.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.